Last updated: March 8, 2026
What Is NDC 62559-0415?
NDC 62559-0415 is the National Drug Code assigned to Vortioxetine, marketed under the brand name Trintellix. It is an antidepressant prescribed primarily for major depressive disorder (MDD). The drug belongs to the class of serotonin modulators and stimulators.
Market Overview
Market Size
In 2022, the U.S. antidepressant market was valued at approximately $13.2 billion and is projected to grow at a compound annual growth rate (CAGR) of around 4% through 2027. Vortioxetine holds an estimated 3-5% share of the prescription antidepressant market.
Market Dynamics
-
Indication Expansion: Clinical trials are exploring vortioxetine's efficacy for generalized anxiety disorder (GAD) and cognitive impairment, potentially expanding its use.
-
Competitive Landscape: The core competitors include:
- Sertraline (Zoloft)
- Escitalopram (Lexapro)
- Duloxetine (Cymbalta)
- Vilazodone (Viibryd)
-
Pricing Trends: The average wholesale price (AWP) for vortioxetine ranges from $560 to $620 per 30-day supply.
-
Prescription Trends: In 2022, approximately 1.2 million prescriptions were dispensed in the U.S., representing a slow but steady increase in demand.
Regulatory and Reimbursement Factors
- The drug has full FDA approval since 2013.
- Reimbursement is primarily through commercial insurance plans, with coverage rates around 90% for covered patients.
- No recent indications or label expansions have been approved post-market.
Price Projections
Short-term (Next 1-2 Years)
-
Wholesale Price: Maintains around $560-$620 per 30-day supply. Slight reductions are possible due to generic competition, but as of 2023, no generic has been approved.
-
Retail Price: Typically $700-$850 after markups and distribution costs.
Long-term (3-5 Years)
- Potential Price Decline: Entry of generics could decrease wholesale prices by 30-50% if approved, targeting $350-$400 per 30 days.
- Market Penetration: Broader acceptance and additional indications could stabilize prices or lead to slight increases if demand expands.
Factors Influencing Price Trends
- FDA Generic Approval: The absence of a generic limits price erosion; approval expected around 2024-2026.
- Insurance Coverage Policies: Changes in formulary placement could affect cash prices.
- Patent Litigation and Exclusivity: Patent expiration in 2029 may encourage generics earlier through specialized pathways.
Competitive Position
Vortioxetine's patented status shields it from generic competition until at least 2029. Its differentiated mechanism offers a niche in treatment-resistant depression, but market share growth is constrained by existing generics, especially after patent expiry.
Summary of Price Expectations
| Time Frame |
Wholesale Price Range |
Notes |
| 2023 |
$560–$620 |
No generic competition; steady pricing |
| 2024–2026 |
$350–$400 |
Potential generic entry if approved |
| 2027–2030 |
$350–$550 |
Market stabilization depending on competition |
Key Takeaways
- The current market for vortioxetine is stable with modest growth.
- Prices are unlikely to decline significantly before 2024 due to the absence of generics.
- Future prices depend on regulatory decisions, patent status, and market expansion.
- Competitive drugs, especially generics, could reduce pricing by half within 3-5 years.
- Market share growth depends on evidence supporting broader indications and clinical acceptance.
FAQs
1. What is the main competitor to vortioxetine?
Selective serotonin reuptake inhibitors such as sertraline and escitalopram dominate the antidepressant market, with some competition from vilazodone.
2. When is a generic version of vortioxetine expected?
Pending patent expiration around 2029; generic approval could occur between 2024 and 2026 depending on patent litigation and FDA outcomes.
3. How do reimbursement policies affect pricing?
Reimbursement rates influence out-of-pocket costs; widespread insurance coverage sustains higher retail prices.
4. Which market factors could accelerate price decline?
Early FDA approval of generics, patent invalidation, and increased market penetration by competitors.
5. What factors could increase the drug's market share?
Label expansion, new indications, and demonstrated superiority in treatment-resistant depression.
References
[1] IQVIA. (2023). Pharmaceutical Market Data.
[2] U.S. Food and Drug Administration. (2013). Approval Letter for Brintellix.
[3] SSR Health. (2022). Prescription Trends for Antidepressants.
[4] Statista. (2023). U.S. Antidepressant Market Revenue.
[5] Evaluate Pharma. (2023). Long-term Market Outlook for Depression Treatments.
